Product Information
FENOFIBRATE 145 MG TABLET is a generic product labeled by Major Pharmaceuticals, priced at $0.1196 per EA under NDC 00904748004. Its NADAC has been published 57 times since Sep 3, 2025.
FDA first approved this application on Dec 23, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
145 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904748004
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
FENOFIBRATEApproval Type
Generic (ANDA)
FDA Application
ANDA090856FDA Approved
12/23/2011
TE Code
AB
On Market Since
2/19/2025
Pharmacological Classes
Price Statistics
The NADAC for FENOFIBRATE 145 MG TABLET has been published 57 times since Sep 3, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1196 per EA |
|---|---|
| All-time high | $0.1214 (Sep 16, 2026) |
| All-time low | $0.1130 (Oct 22, 2025) |
| 52-week high | $0.1214 |
| 52-week low | $0.1130 |
| Median price | $0.1185 |
| Average price | $0.1179 |
| Largest weekly change | -6.2% (Sep 17, 2025) |
| Weeks tracked | 57 |
| Tracking since | Sep 3, 2025 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Fenofibrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Peroxisome Proliferator Receptor alpha Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FENOFIBRATE 145 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for FENOFIBRATE 145 MG TABLET, manufactured by Major Pharmaceuticals, is $0.1196 per EA (NDC 00904748004), effective Sep 30, 2026.
How has the price of FENOFIBRATE 145 MG TABLET changed over time?
Over the history we have for it, the NADAC for FENOFIBRATE 145 MG TABLET has held within roughly two percent of its current level. It has been tracked across 57 weekly CMS publications since Sep 3, 2025.
What are the highest and lowest recorded NADAC prices for FENOFIBRATE 145 MG TABLET?
Since Sep 3, 2025, the NADAC for FENOFIBRATE 145 MG TABLET has ranged from a low of $0.1130 (Oct 22, 2025) to a high of $0.1214 (Sep 16, 2026), with a median of $0.1185 per EA.
Are there cheaper alternatives to FENOFIBRATE 145 MG TABLET?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as FENOFIBRATE 145 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures FENOFIBRATE 145 MG TABLET?
FENOFIBRATE 145 MG TABLET (NDC 00904748004) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.